৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.



Quantity:
Products
Payment
Delivery
Montaro (Tirzepatide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
Not studied in patients with history of pancreatitis.
Not indicated for type 1 diabetes mellitus.
Pharmacology: Tirzepatide is a dual GIP and GLP‑1 receptor agonist. It is a 39‑amino‑acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs half‑life. It enhances first‑ and second‑phase insulin secretion and reduces glucagon levels in a glucose‑dependent manner.
Dosage & Administration:
Route: Subcutaneous injection.
Starting dose: 2.5 mg once weekly (for initiation only, not for glycemic control).
After 4 weeks: Increase to 5 mg once weekly.
Further titration: Increase in 2.5 mg increments after ≥4 weeks on current dose.
Maximum dose: 15 mg once weekly.
Missed dose: Administer within 4 days; otherwise skip and resume regular schedule.
Injection sites: Abdomen, thigh, or upper arm (rotate sites).
Do not freeze, do not mix with other drug solutions, protect from light.
Drug Interactions:
Reduce dose of sulfonylureas or insulin to lower hypoglycemia risk.
May delay gastric emptying, affecting absorption of oral drugs.
Oral contraceptives: Advise non‑oral or barrier method for 4 weeks after initiation and dose escalation.
Contraindications:
Hypersensitivity to Tirzepatide or components.
Personal/family history of medullary thyroid carcinoma (MTC) or MEN 2.
Side Effects: Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.
Pregnancy & Lactation: Use only if potential benefit outweighs risk. Consider maternal clinical needs and potential effects on breastfed infant.
Precautions & Warnings:
Counsel patients on risk of thyroid tumors (MTC).
Monitor for pancreatitis, renal function, gallbladder disease, and diabetic retinopathy progression.
Discontinue if hypersensitivity occurs.
Use in Special Populations: Safety not established in children <10 years.
Overdose Effects: Supportive treatment based on symptoms; half‑life ~5 days.
Storage Conditions: Store at 2–8 °C in refrigerator. Do not freeze. Protect from light. Keep out of reach of children. Dispense only on registered physician’s prescription.


Tirzepatide is an injectable medication used for type 2 diabetes management and, in many cases, weight management. It works as a dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar and appetite.
Tirzepatide helps lower blood glucose levels, improve insulin sensitivity, reduce appetite, and support significant weight loss. It may also reduce cardiovascular risk factors in patients with type 2 diabetes.





